186 related articles for article (PubMed ID: 24367201)
1. Potential of afatinib in the treatment of patients with HER2-positive breast cancer.
Geuna E; Montemurro F; Aglietta M; Valabrega G
Breast Cancer (Dove Med Press); 2012 Aug; 4():131-7. PubMed ID: 24367201
[TBL] [Abstract][Full Text] [Related]
2. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M; Awada A; Harter P; Canon JL; Possinger K; Schmidt M; De Grève J; Neven P; Dirix L; Jonat W; Beckmann MW; Schütte J; Fasching PA; Gottschalk N; Besse-Hammer T; Fleischer F; Wind S; Uttenreuther-Fischer M; Piccart M; Harbeck N
Breast Cancer Res Treat; 2012 Aug; 134(3):1149-59. PubMed ID: 22763464
[TBL] [Abstract][Full Text] [Related]
4. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Lin NU; Winer EP; Wheatley D; Carey LA; Houston S; Mendelson D; Munster P; Frakes L; Kelly S; Garcia AA; Cleator S; Uttenreuther-Fischer M; Jones H; Wind S; Vinisko R; Hickish T
Breast Cancer Res Treat; 2012 Jun; 133(3):1057-65. PubMed ID: 22418700
[TBL] [Abstract][Full Text] [Related]
6. Afatinib in the treatment of breast cancer.
Hurvitz SA; Shatsky R; Harbeck N
Expert Opin Investig Drugs; 2014 Jul; 23(7):1039-47. PubMed ID: 24870559
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
8. Afatinib in the treatment of head and neck squamous cell carcinoma.
Ferrarotto R; Gold KA
Expert Opin Investig Drugs; 2014 Jan; 23(1):135-43. PubMed ID: 24266694
[TBL] [Abstract][Full Text] [Related]
9. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
10. Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
Di Luca A; Henry M; Meleady P; O'Connor R
Daru; 2015 Aug; 23(1):40. PubMed ID: 26238995
[TBL] [Abstract][Full Text] [Related]
11. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
16. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
Hickish T; Mehta A; Liu MC; Huang CS; Arora RS; Chang YC; Yang Y; Vladimirov V; Jain M; Tsang J; Pemberton K; Sadrolhefazi B; Jin X; Tseng LM
Breast Cancer Res Treat; 2022 Apr; 192(3):593-602. PubMed ID: 35138529
[TBL] [Abstract][Full Text] [Related]
17. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Awada A; Bozovic-Spasojevic I; Chow L
Cancer Treat Rev; 2012 Aug; 38(5):494-504. PubMed ID: 22305205
[TBL] [Abstract][Full Text] [Related]
18. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Bowles DW; Weickhardt A; Jimeno A
Drugs Today (Barc); 2013 Sep; 49(9):523-35. PubMed ID: 24086949
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Duchnowska R; Loibl S; Jassem J
Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
